Related Experiment Video
Updated: May 16, 2026

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
Published on: September 8, 2021
Lack of BRAF V600E protein expression in primary central nervous system lymphoma
Anna S Berghoff1, David Capper, Matthias Preusser
1Department of Neuropathology, Institute of Neurology, Medical University of Vienna, Vienna, Austria.
Background:
Mutations in the v-raf murine sarcoma viral oncogenes homolog B1 (BRAF), most commonly of the V600E type, are present in a variety of human malignancies including malignant melanoma, papillary thyroid cancers, and hairy-cell leukemia and specific therapeutically active BRAF inhibitors exist. We aimed to investigate BRAF V600E protein expression in primary central nervous system lymphoma (PCNSL).
Methods:
We investigated BRAF V600E expression in formalin-fixed and paraffin-embedded surgical tissue specimens of 20 immunocompetent patients with PCNSL using the mutation-specific monoclonal mouse antibody VE1.
Results:
Ten male and 10 female patients with a median age of 60 years (range, 44 to 71 y) at time of operation were included. All cases were qualified as diffuse large B-cell lymphomas. None of the investigated cases demonstrated specific immunoreactivity for BRAF V600E mutation.
Conclusions:
Our data provide evidence that the BRAF V600E mutation is not pathobiologically relevant in PCNSL and as a consequence is not a feasible drug target in this tumor type.
Insights
The BRAF V600E mutation is not found in primary central nervous system lymphoma (PCNSL). Therefore, BRAF V600E is not a viable drug target for treating this rare cancer.
Area of Science:
- Oncology
- Molecular Biology
- Immunohistochemistry
Background:
- BRAF V600E mutations are common in various cancers like melanoma and thyroid cancer.
- Targeted BRAF inhibitors are effective treatments for these malignancies.
- The role of BRAF V600E in primary central nervous system lymphoma (PCNSL) was previously unclear.
Purpose of the Study:
- To determine the expression of BRAF V600E protein in primary central nervous system lymphoma (PCNSL).
- To assess the potential of BRAF V600E as a therapeutic target in PCNSL.
Main Methods:
- BRAF V600E expression was analyzed in 20 PCNSL tissue specimens.
- Immunohistochemistry using the mutation-specific VE1 antibody was employed.
- Specimens were formalin-fixed and paraffin-embedded.
Main Results:
- The study included 20 immunocompetent patients (10 male, 10 female) with a median age of 60.
- All PCNSL cases were classified as diffuse large B-cell lymphomas.
- No specific immunoreactivity for the BRAF V600E mutation was detected in any of the samples.
Conclusions:
- The BRAF V600E mutation is not pathobiologically relevant in PCNSL.
- BRAF V600E does not represent a feasible drug target for PCNSL treatment.
- This finding impacts the development of targeted therapies for PCNSL.
Related Concept Videos
Primary Lymphoid Organs
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
Lymphoid Cells and Tissues
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
Abnormal Proliferation

